Accelerating Medical Discovery Through Simulation
Testing medical innovation should not depend on waiting years for access to patients, data, and approvals
The Problem
8%
Only a small fraction of healthcare data is readily usable for research and AI
The Healthcare Innovation Paradox
Healthcare generates more data than ever before.
Yet many promising ideas never get tested because access to longitudinal clinical data remains expensive, fragmented, and slow.
Innovation is not limited by imagination.
It is limited by the ability to safely experiment.
What We Believe
Validation Matters
AI models should be trusted because they are validated, not because they are impressive
Privacy Matters
Innovation should not require exposing sensitive patient data
Simulation Matters
The future of healthcare will increasingly be tested before it is deployed
Impact Stories
When a Rare Cancer Has Too Few Patients
A research team studying advanced sarcoma faced a familiar challenge: too few patients to confidently explore alternative treatment strategies. Using comparable synthetic populations, researchers were able to investigate longitudinal treatment trajectories, compare outcomes across studies, and explore questions that would otherwise remain unanswered. The goal was not to replace clinical research. The goal was to ask better questions before investing years in the real world.
When an AI Model Cannot Be Validated
A healthcare technology company had developed a promising oncology algorithm. Building the model was not the challenge. Proving it worked was! Synthetic clinical populations allowed the team to stress-test assumptions, explore performance across patient profiles, and prepare a stronger validation strategy before real-world deployment. Because in healthcare, validation is often harder than innovation itself.
Before Changing Care for Thousands of Patients
Imagine implementing a new treatment pathway across an entire healthcare system. What if different strategies could be explored before affecting real patients? Simulation makes it possible to compare scenarios, evaluate potential outcomes, and understand risks before implementation. Not to replace reality. To better prepare for it.
Why æqualis Exists
Healthcare advances through experimentation.
Yet many promising ideas never reach evaluation because testing them requires access to patients, data, time, funding, and regulatory pathways.
We believe innovation should not be limited by the availability of data.
We are building the simulation infrastructure needed to accelerate medical discovery.
Recognition & Momentum
March, 2025
Secured non-dilutive funding to accelerate clinical simulation research
1st round of non dilutive grant EMBRAPII-SEBRAE
September, 2025
September, 2025
Acceleration Program
Finalist of the acceleration program Juntos Inovamos Coop from Horizontes HUB / Unimedbh click here
October, 2025
Protected core technologies supporting future clinical simulation infrastructure
Patents: BR 10 2025 023693 1 and BR 10 2025 023697 4
November, 2025
Finalist AC Camargo Next Frontiers 2025
Independent experts recognized the potential of simulation to accelerate oncology innovation
February, 2026
Pre incubation program
Selected as finalist on Inova Lab UFMG round 3
March, 2026
PoC validation
Jun, 2026
Embrapii-SEBRAE grant
2nd round non dilutive grant.
Join the Future of Clinical Simulation
æqualis® is looking for visionary partners — from research labs to academic consortia — who believe that ethical, scalable, and innovative data can shape the next frontier of discovery